Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
blocks opioid receptors
|
| gptkbp:appointed_by |
oral tablet
injectable solution |
| gptkbp:approves |
gptkb:1984
gptkb:FDA |
| gptkbp:brand |
gptkb:Vivitrol
Depade Re Via |
| gptkbp:class |
gptkb:superhero
|
| gptkbp:clinical_trial |
alcohol dependence
opioid dependence |
| gptkbp:contraindication |
opioid dependence
acute opioid withdrawal |
| gptkbp:developed_by |
gptkb:Endo_Pharmaceuticals
|
| gptkbp:excretion |
urine
|
| gptkbp:formulation |
oral tablet
oral solution extended-release injection |
| https://www.w3.org/2000/01/rdf-schema#label |
naltrexone
|
| gptkbp:ingredients |
C20 H23 N3 O2
|
| gptkbp:interacts_with |
gptkb:buprenorphine
gptkb:naltrexone opioids |
| gptkbp:is_atype_of |
N07 B B04
|
| gptkbp:is_available_on |
generic drug
|
| gptkbp:is_used_for |
treatment of alcohol dependence
treatment of opioid addiction |
| gptkbp:lifespan |
4 hours
|
| gptkbp:manager |
subcutaneous
intramuscular |
| gptkbp:metabolism |
liver
|
| gptkbp:population |
adults
adolescents individuals with alcohol use disorder individuals with opioid use disorder |
| gptkbp:research_areas |
mental health
substance use disorder pharmacotherapy addiction medicine |
| gptkbp:safety_features |
generally well tolerated
risk of liver damage with high doses |
| gptkbp:side_effect |
dizziness
fatigue headache nausea |
| gptkbp:traded_on |
gptkb:Vivitrol
Re Via |
| gptkbp:type_of |
16595-80-5
|
| gptkbp:bfsParent |
gptkb:Naltrexone
|
| gptkbp:bfsLayer |
6
|